Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc (NOVT) delivers precision photonic components and motion-control systems powering innovations in medical technology and industrial automation. This dedicated news hub provides investors and industry professionals with direct access to official press releases and verified updates about the company's technological advancements.
Discover comprehensive coverage of Novanta's latest developments including product launches for minimally invasive surgery tools, strategic partnerships in robotics, and innovations in laser-based manufacturing systems. Our curated feed ensures you stay informed about earnings announcements, leadership updates, and patent filings that demonstrate NOVT's leadership in mission-critical OEM solutions.
Key updates focus on the company's Medical Solutions segment enhancing surgical workflows and Automation Enabling Technologies driving smart manufacturing. Track progress in RFID-based hospital systems and high-precision components for additive manufacturing – all critical to Novanta's dual-market strategy.
Bookmark this page for streamlined access to NOVT's evolving role in medical device innovation and industrial automation. Check regularly for authoritative updates on photonics advancements and motion-control technologies shaping next-generation healthcare and manufacturing ecosystems.
Novanta Inc. (NASDAQ: NOVT) will release its Q1 2023 results on May 9, 2023. A conference call is scheduled for 10:00 a.m. ET on the same day to discuss the financial performance. Investors can participate by dialing (888) 346-3959 or through a live webcast available on the company’s website. A replay of the call will be accessible approximately three hours after its conclusion and will remain available until July 3, 2023. Novanta is recognized as a leading global supplier of technology solutions for healthcare and industrial OEMs, providing advanced components and systems designed for precision and superior performance.
Novanta reported a strong financial performance for the full year 2022, with GAAP revenue increasing by 22% to $861 million and net income rising to $74 million. The company achieved a 46% increase in diluted EPS, reaching $2.06. Adjusted EPS also grew by 17% to $3.07, while adjusted EBITDA was reported at $184 million. For Q4 2022, revenue rose 9.8% to $218.4 million. Looking ahead, Novanta projects 2023 GAAP revenue between $890 million and $915 million with adjusted diluted EPS expected between $3.00 and $3.20.
Novanta Inc. (NASDAQ: NOVT) will announce its fourth quarter and full year 2022 results on March 1, 2023. The company is a trusted partner for medical and advanced technology equipment manufacturers, offering core technology solutions to enhance performance. A conference call is scheduled for 10:00 a.m. ET on the same day to discuss results, accessible via phone or a live webcast through its website. A replay of the call will be available for three hours after the event until April 3, 2023. For more information, visit Novanta's website.
Novanta Inc. (NASDAQ: NOVT), a leader in technology solutions for medical and advanced technology equipment manufacturers, announced that Robert Buckley, CFO, and Chuck Ravetto, Group President, will present at the CJS Securities 23rd Annual New Ideas for the New Year Investor Conference on Wednesday, January 11, 2023. The conference will be held virtually, highlighting Novanta's commitment to innovation and customer success as they deliver precise technology solutions to OEMs.
Novanta Inc. (NASDAQ: NOVT) announced that its Chair & CEO, Matthijs Glastra, along with CFO Robert Buckley, will present at the J.P. Morgan Healthcare Conference in San Francisco, California, on January 10, 2023. As a global supplier of technology solutions for medical and advanced industrial OEMs, Novanta specializes in photonics, vision, and precision motion technologies. The company's expertise enables it to deliver high-performance components tailored to customer needs, driving growth through innovation and commitment to success.
Novanta reported a 26% increase in GAAP revenue to $223 million for Q3 2022, alongside a 66% rise in diluted EPS to $0.63. The company posted a net income of $22 million, up from $13.6 million year-over-year. Adjusted EBITDA was $49 million, reflecting robust performance despite inflationary pressures. Novanta raised its 2022 guidance, expecting GAAP revenue of $857-$859 million for the year, indicating 21-22% growth. Customer demand remains strong, with backlog levels near record highs.
FAQ
What is the current stock price of Novanta (NOVT)?
What is the market cap of Novanta (NOVT)?
